<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702490</url>
  </required_header>
  <id_info>
    <org_study_id>MET409-201</org_study_id>
    <nct_id>NCT04702490</nct_id>
  </id_info>
  <brief_title>Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH</brief_title>
  <official_title>A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metacrine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metacrine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with&#xD;
      empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and&#xD;
      placebo-controlled. Empagliflozin will be incorporated into two of the treatment arms in an&#xD;
      open-label manner.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects assigned to receive empagliflozin will be dosed at 10 mg per day for the duration of&#xD;
      the study.&#xD;
&#xD;
      Approximately 30 subjects will be enrolled per treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MET409 with or without empagliflozin (incidence of adverse events)</measure>
    <time_frame>Up to 28 days after last dose</time_frame>
    <description>Incidence of Treatment-emergent adverse events, incidence of clinically significant changes in vital signs, abnormal laboratory safety tests, and abnormal ECGs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacological activity of MET409 alone or in combination with empagliflozin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of MET409 alone or in combination with empagliflozin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of MET409 alone or in combination with empagliflozin</measure>
    <time_frame>12 weeks</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of MET409 alone or in combination with empagliflozin</measure>
    <time_frame>12 weeks</time_frame>
    <description>AUClast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile of MET409 alone or in combination with empagliflozin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Bile acid precursor : C4 (7αhydroxy-4-cholesten-3-one)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile of MET409 alone or in combination with empagliflozin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Bile acid precursor : Fibroblast growth factor 19 (FGF19)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>NASH</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetes Type 2</condition>
  <condition>Diabetes</condition>
  <condition>Fatty Liver</condition>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>MET409 A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MET409 Active (50mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MET409 P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MET409 Placebo (50mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MET409A +Open-Label Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MET409 Active (50mg) + Empagliflozin (10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MET409P +Open-Label Empagliflozin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MET409 Placebo (50mg) + Empagliflozin (10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MET409 Active</intervention_name>
    <description>MET409 Active (50mg)</description>
    <arm_group_label>MET409 A</arm_group_label>
    <arm_group_label>MET409A +Open-Label Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MET409 Placebo</intervention_name>
    <description>MET409 Placebo (50mg)</description>
    <arm_group_label>MET409 P</arm_group_label>
    <arm_group_label>MET409P +Open-Label Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin (10mg)</description>
    <arm_group_label>MET409A +Open-Label Empagliflozin</arm_group_label>
    <arm_group_label>MET409P +Open-Label Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18 through 75 years of age.&#xD;
&#xD;
          -  Diagnosis of NASH based on NAFLD Activity Score (NAS) ≥ 4 with at least 1 point in&#xD;
             each of steatosis, inflammation, and ballooning; Magnetic Resonance Elastography (MRE)&#xD;
             showing kPa ≥ 2.61 or a multiparametric MRI (ie, LiverMultiScan) showing&#xD;
             iron-corrected T1(cT1) &gt; 830 ms within 6 months of enrollment; or Transient&#xD;
             elastography (TE, FibroScan) with liver stiffness ≥ 8.5 kPa and controlled attenuation&#xD;
             parameter (CAP) &gt; 300 dB/m obtained within 3 months of enrollment.&#xD;
&#xD;
          -  Liver fat content ≥ 8% measured by magnetic resonance imaging-proton density fat&#xD;
             fraction (MRI-PDFF) during screening.&#xD;
&#xD;
          -  Diagnosis of T2DM for ≤ 10 years, with hemoglobin A1c ≤ 10.0% during screening, stable&#xD;
             and controlled with diet or treatment for at least 3 months.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of significant liver disease (eg, alcoholic liver disease, viral hepatitis,&#xD;
             etc.) or liver transplant.&#xD;
&#xD;
          -  Presence of cirrhosis on any prior liver biopsy (stage 4 fibrosis).&#xD;
&#xD;
          -  Excessive consumption of alcohol.&#xD;
&#xD;
          -  Use of any insulin (injectable or inhaled), SGLT-2 inhibitor or glucagon-like peptide&#xD;
             1 (GLP-1, injectable or oral) products for &gt; 7 days within 3 months of screening.&#xD;
&#xD;
          -  Weight loss &gt; 10% in the 6 months prior to screening or &gt; 5% during screening.&#xD;
&#xD;
          -  Use of drugs historically associated with causing NAFLD for more than 4 consecutive&#xD;
             weeks within 12 months prior to screening.&#xD;
&#xD;
          -  Concomitant use of drugs that are strong or moderate CYP3A4 inhibitors.&#xD;
&#xD;
          -  Concomitant consumption of grapefruit juice with the study drug.&#xD;
&#xD;
          -  History of diabetic ketoacidosis (DKA) within 1 month prior to the Screening Visit, or&#xD;
             more than 2 episodes within 6 months prior to the Screening Visit.&#xD;
&#xD;
          -  History of &gt; 2 episodes of urosepsis or pyelonephritis within 5 years of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert C Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Metacrine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metacrine Investigative Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metacrine Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.metacrine.com/</url>
    <description>Metacrine</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>FXR</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

